Clinical trial
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
NCT00002233 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002233 |
|---|---|
| Title | A Study of a Combination of Four Drugs in Patients With Recent HIV Infection |
| Official title | A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Quadruple Antiretroviral Therapy (EPIVIR, Abacavir, Amprenavir, and Indinavir) in Subjects Acutely Infected With HIV-1 |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine |
| Enrollment | 30 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: